Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer
The aims of this trial are to evaluate the efficacy and tolerability of pemetrexed + paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer.
Thyroid Cancer
DRUG: pemetrexed + paclitaxel
Rate of response, 6 weeks
Toxicity, weekly
The aims of this trial are to evaluate the efficacy and tolerability of pemetrexed + paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer.